NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, reported its fiscal year 2026 results, showcasing significant clinical and regulatory progress for its broad-spectrum antiviral candidate NV-387. The company received regulatory approval in the Democratic Republic of Congo to initiate Phase II trials evaluating NV-387 Oral Gummies for the treatment of Mpox and Ebola, with both trials beginning enrollment at the end of September 2026. Additionally, the U.S. Food and Drug Administration granted Orphan Drug Designation and Rare Pediatric Disease Drug designation for NV-387 as a treatment for measles. These milestones position NanoViricides at the forefront of developing therapies for neglected and emerging viral threats.
Financially, NanoViricides reported approximately $2.79 million in cash and cash equivalents as of June 30, 2026, up from approximately $1.67 million a year earlier. The company raised approximately $9.01 million through registered direct and at-the-market equity offerings during fiscal 2026 and subsequently raised approximately $3.8 million in July 2026. Management stated it is pursuing additional funding through grants and contracts, partnerships, debt, or equity financing to support its ongoing clinical programs. This improved cash position provides a runway to advance NV-387 through mid-stage trials, a critical phase that often determines a drug's viability.
NV-387 is a novel nanoviricide designed to combat a wide range of viral infections, including RSV, COVID-19, Long COVID, influenza, and other respiratory viruses, as well as MPOX/Smallpox and measles. The company's other advanced candidate, NV-HHV-1, targets shingles. NanoViricides' technology is based on intellectual property licensed from TheraCour Pharma, Inc., and the company holds worldwide exclusive licenses for several viral diseases, including HIV, Hepatitis B and C, Rabies, Herpes Simplex, Varicella-Zoster, Influenza, Dengue, Japanese Encephalitis, West Nile, and Ebola/Marburg viruses.
The news matters because it demonstrates tangible progress in developing broad-spectrum antivirals that could address multiple high-priority pathogens with a single platform. The approval to conduct Phase II trials in the DRC for Mpox and Ebola—diseases with limited treatment options and high outbreak potential—could lead to new therapies for regions prone to epidemics. The FDA designations for measles, a resurgent threat in unvaccinated populations, may expedite development and provide incentives such as market exclusivity. For investors, the strengthened balance sheet and ability to raise capital signal confidence in the company's pipeline, though drug development remains lengthy and capital-intensive with inherent risks. The broader industry may see increased interest in nanomedicine-based antivirals, potentially reshaping treatment paradigms for viral diseases.
For more details, the full press release is available at https://ibn.fm/s000r. The company's website is www.nanoviricides.com. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.
MissionIR, a specialized communications platform, distributed this announcement. MissionIR is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution.
